ANRO · Alto Neuroscience
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $38.00
Note written ·
Price against the kill line
22.3% clear of its kill line on the 13 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 13 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $38.00, on record since 11 November 2026. The shares are down 12.1% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $38.00, over the 52-week intraday high of $37.48 set on 25 August 2026, which would show the shares leading again. A positive ALTO-300 Phase 2b topline that meets its primary endpoint would also show the call is wrong.
Research onlyNot in the portfolio.
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 10 November 2026; valuation at the 13 November 2026 close
- Free cash flow, four quarters ($M)
- −79.7
- Net cash, cash less debt ($M)
- 306
- Free-cash-flow yield (%)
- −6.7
All filed numbers
What Alto Neuroscience reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Pre-tax income ($M) | Not reported |
| Net income ($M) four quarters: −95.2 | −25.1 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +71.7 |
| Operating cash flow ($M) | −79.1 |
| Capital spending ($M) | 0.6 |
| Free cash flow ($M) | −79.7 |
| Cash and short-term investments ($M) | 319 |
| Debt ($M) non-current long-term debt plus current maturities | 13.5 |
| Net cash, cash less debt ($M) | 306 |
| Deferred revenue ($M) | Not reported |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | Not reported |
| Inventory ($M) | Not reported |
| Shareholders' equity ($M) | 297 |
| Market value ($M) | 1,185 |
| Enterprise value, market value plus net debt ($M) | 879 |
| Enterprise value to sales (×) | Not available |
| Enterprise value to operating income (×) | Not meaningful |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | 4.0 |
| Free-cash-flow yield (%) | −6.7 |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 13.0% of shares outstanding sold short, 7.5 days of average trading to cover, +11.7% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $3.6M |
| 12 monthsfrom | $0 | $3.6M |
The thesis
Alto Neuroscience's depression program is funded through 2030 on company guidance, and the third-quarter report on 10 November 2026 left every clinical timeline intact. The shares are still more likely to lag the S&P 500 over the next three months, because no efficacy data is due until the first half of 2027 and the price has already moved sharply. The ALTO-300 Phase 2b topline, guided for 1H 2027, settles the call.
Alto is a pre-revenue, clinical-stage company with no approved product. Its 10 November 2026 release reported $319.8 million in cash, cash equivalents and restricted cash at 30 September 2026, against about $177.0 million at 31 December 2025, and said cash is expected to fund planned operations through 2030 (Form 8-K exhibit 99.1).
The shares closed at $21.87 on 5 November 2026 and at $30.62 on 12 November 2026, with a high close of $31.15 on 11 November 2026. The 12 November 2026 close is above the $26.48 price of the July 2026 registered direct offering.
Bullish and bearish views on Alto Neuroscience Inc.
The bull case on Alto Neuroscience Inc. (ANRO), in brief: cash covers the guided calendar. The bear case: no efficacy readout for months.
Bull case
- Cash covers the guided calendar. The 10 November 2026 release reported $319.8 million at 30 September 2026 and guided funding through 2030, past the planned ALTO-207 Phase 3 starts.
- Spending fell from the second quarter. Third-quarter research and development expense was $18.2 million against $22.1 million in the second quarter, and the net loss was $25.1 million against $27.6 million (company releases of 10 November 2026 and 12 August 2026).
- Loss per share beat the estimate. Benzinga reported third-quarter loss per share of $(0.54) against an estimate of $(0.67) on 10 November 2026.
- Timelines held. The 10 November 2026 release kept PACE-2 (ALTO-207 Phase 3, adjunctive treatment-resistant depression) initiation in early 2027, ALTO-300 topline in 1H 2027, ALTO-100 topline in mid-2027 and PACE-1 topline in 2H 2027.
- Analyst support after the report. BTIG reiterated Buy with a $37 target on 11 November 2026 (Benzinga).
Bear case
- No efficacy readout for months. The first company-guided data, ALTO-300 in major depressive disorder, is due in 1H 2027, and PACE-1 follows in 2H 2027.
- PACE-2 still depends on the FDA. The 10 November 2026 release described PACE-2 initiation in early 2027 as pending Food and Drug Administration alignment on trial design. PACE-3, the monotherapy Phase 3, is listed for 2H 2027 on the same condition.
- A prior mid-stage miss. ALTO-101 missed its Phase 2 primary endpoint in schizophrenia-related cognitive impairment in April 2026 (p=0.052), and independent development was dropped.
- Costs are well above a year ago. Third-quarter research and development expense was $18.2 million versus $10.5 million in the third quarter of 2025. General and administrative expense was $9.1 million versus $4.4 million, and the net loss was $25.1 million versus $14.2 million (10 November 2026 release).
- Equity raises have followed price strength. Alto sold $100 million of stock at $26.48 on 13 July 2026, after a $120 million private placement at $20.00 in March 2026. The shares now trade above both prices.
- A senior insider sold into the rally. President and Chief Financial Officer Nicholas Smith exercised 134,886 options at $2.35 and sold 134,886 shares at an average of $26.45 on 29 September to 30 September 2026 (SEC Form 4, filed 1 October 2026).
Price setup
The last close was $30.62 on 12 November 2026, 18.3% below the 52-week high of $37.48 (intraday, 25 August 2026). The 3-month change is −4.7%. The 52-week closing low is $11.35 on 13 November 2025.
The shares sit above both moving averages: the 50-day average is $26.5 and the 200-day average is $24.66 (adjusted closes as of 12 November 2026). Closes rose from $21.87 on 5 November 2026 to $25.16 on 6 November 2026, $27.80 on 9 November 2026, $28.61 on 10 November 2026 and $31.15 on 11 November 2026, then slipped to $30.62 on 12 November 2026.
Most of that rise came before or on the day of the report. The only company news in the period was the earnings notice and the investor-conference notice. The 14 August 2026 close of $32.14, the three-month reference, is the next price above the last close that the shares have recently traded at.
Catalysts ahead
- ~31 January 2027 (est.): Phase 1 modified-release formulation results and blinded PACE-1 safety data. The company guided these for late 2026 or early 2027 depending on FDA feedback; they are the first clinical updates after the Q3 report.
- ~31 March 2027 (est.): PACE-2 Phase 3 initiation for ALTO-207. The company guided early 2027, pending FDA alignment on design; a slip would weaken the funded-program case.
- ~30 June 2027 (est.): ALTO-300 Phase 2b topline in major depressive disorder. The first company-guided efficacy readout; it tests the precision-psychiatry approach after the April 2026 ALTO-101 miss.
What would change the view
A daily close above $38.00, over the 52-week intraday high of $37.48 set on 25 August 2026, which would show the shares leading again. A positive ALTO-300 Phase 2b topline that meets its primary endpoint would also show the call is wrong.
What it trades with
Alto trades with small- and mid-cap clinical-stage biotech, so moves in the SPDR S&P Biotech ETF (XBI) and in funding conditions for pre-revenue drug developers carry into the shares. Its own drivers are the timing of ALTO-207 and ALTO-300 and the risk of another equity raise, not revenue. Trial results from other psychiatric drug developers can move the shares without any Alto news.
The evidence, claim by claim (7)
- Cash, cash equivalents and restricted cash were $319.8 million at 30 September 2026; the company expects cash to fund planned operations through 2030. Alto Neuroscience Q3 2026 results release (Form 8-K exhibit 99.1) · as of
- Third-quarter R&D expense was $18.2 million (vs $10.5 million a year earlier), G&A $9.1 million (vs $4.4 million) and net loss $25.1 million (vs $14.2 million); loss per share was $(0.54). Alto Neuroscience Q3 2026 results release (Form 8-K exhibit 99.1) · as of
- Guided timing: PACE-2 Phase 3 initiation early 2027 (pending FDA alignment), ALTO-300 Phase 2b topline 1H 2027, ALTO-100 Phase 2b topline mid-2027, PACE-1 topline 2H 2027. Alto Neuroscience Q3 2026 results release (Form 8-K exhibit 99.1) · as of
- BTIG reiterated Buy on Alto Neuroscience with a $37 price target. Benzinga · as of
- President and CFO Nicholas Smith sold 134,886 shares at an average of $26.45 on 29 September to 30 September 2026 after exercising options at $2.35. SEC Form 4 filed 1 October 2026 · as of
- Alto priced a $100.0 million registered direct offering of 3,776,436 shares at $26.48. Alto Neuroscience press release · as of
- Third-quarter loss per share of $(0.54) beat the $(0.67) estimate. Benzinga · as of
Sources
- Alto Neuroscience, Inc. - Form 8-K - FY2026 · sec.gov ·
- Alto Neuroscience, Inc. - Form 8-K - FY2026 · sec.gov
- BioPharmaWatch ·
Related · shared themes
ZVRA
Zevra Therapeutics
Zevra Therapeutics is modestly more likely to beat the S&P 500 over three months: MIPLYFFA sold $34.0 million in the third quarter of 2026…
ABCL
AbCellera Biologics
AbCellera's shares look more likely to lag the S&P 500 over three months, because the case rests on unproven repeat dosing of ABCL635, its…
IBRX
ImmunityBio
ImmunityBio's third-quarter Anktiva revenue of $48.7 million fell below the second quarter's $50.7 million, and the shares are more likely…
KOD
Kodiak Sciences
Kodiak Sciences' shares look more likely to lag the S&P 500 after a 161.8% three-month run that prices in the DAYBREAK win while share…